Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13981746 | 0.89 | CXCR5 (0.45) | CXCR5OPRM1MEN1KMT2ABRD4 | |
| SCHEMBL13360290 | 0.87 | MEN1 (0.38) | CXCR5OPRM1MEN1KMT2ABRD4 | |
| SCHEMBL3304678 | 0.78 | OPRM1 (0.37) | CXCR5OPRM1MEN1KMT2ABRD4 | |
| Hydrochloric Acid SCHEMBL3306425 | 0.77 | OPRM1 (0.39) | CXCR5OPRM1MEN1KMT2ABRD4 | |
| SCHEMBL3312092 | 0.77 | CXCR5 (0.58) | CXCR5 | |
| SCHEMBL3305054 | 0.75 | OPRM1 (0.35) | CXCR5OPRM1MEN1KMT2ABRD4 | |
| SCHEMBL13981766 | 0.74 | CXCR5 (0.39) | CXCR5OPRM1MEN1KMT2ABRD4 | |
| SCHEMBL3310445 | 0.74 | CXCR5 (0.78) | CXCR5 | |
| SCHEMBL9886521 | 0.68 | MGAM (0.39) | OPRM1MEN1KMT2AOPRD1OPRK1 | |
| SCHEMBL29203032 | 0.68 | OPRM1 (0.40) | OPRM1MEN1KMT2ABRD4OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | CXCR5 1/4885OPRM1 619/4885MEN1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.